Journal
FUTURE ONCOLOGY
Volume 17, Issue 33, Pages 4425-4429Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-0955
Keywords
brain metastases; craniopharyngioma; glioblastoma; leptomeningeal metastases; meeting report; neuro-oncology
Categories
Funding
- NIH [P50 CA221747]
Ask authors/readers for more resources
This report reviews key studies presented at the ASCO 2021 annual meeting, including major phase III, II, and I trials, important advances in primary brain tumor management, and research on exploratory CSF biomarkers. The research highlighted important advancements in neuro-oncology topics that may impact future research and clinical practice.
In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available